<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 17 Lupus nephritis | LATINART</title>
  <meta name="description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="generator" content="bookdown 0.32 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 17 Lupus nephritis | LATINART" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/logo.png" />
  <meta property="og:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 17 Lupus nephritis | LATINART" />
  
  <meta name="twitter:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="twitter:image" content="/logo.png" />

<meta name="author" content="Robert W Hunter" />


<meta name="date" content="2023-03-07" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="anca-vasculitis.html"/>
<link rel="next" href="adpkd.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="https://www.kidneyfish.net">KidneyFish</a></li>
<li><a href="./">LATINART</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="1" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="intro.html"><a href="intro.html#types-of-study"><i class="fa fa-check"></i><b>1.1</b> Types of study</a></li>
<li class="chapter" data-level="1.2" data-path="intro.html"><a href="intro.html#other-lists-of-landmark-trials"><i class="fa fa-check"></i><b>1.2</b> Other lists of ‘landmark’ trials</a></li>
<li class="chapter" data-level="1.3" data-path="intro.html"><a href="intro.html#going-deeper"><i class="fa fa-check"></i><b>1.3</b> Going deeper</a></li>
<li class="chapter" data-level="1.4" data-path="intro.html"><a href="intro.html#recent-trials-see-twitter-feed"><i class="fa fa-check"></i><b>1.4</b> Recent trials: see Twitter feed</a></li>
</ul></li>
<li class="part"><span><b>I AKI</b></span></li>
<li class="chapter" data-level="2" data-path="aki.html"><a href="aki.html"><i class="fa fa-check"></i><b>2</b> AKI</a>
<ul>
<li class="chapter" data-level="2.1" data-path="aki.html"><a href="aki.html#aki-trials-in-other-chapters"><i class="fa fa-check"></i><b>2.1</b> AKI trials in other chapters</a></li>
<li class="chapter" data-level="2.2" data-path="aki.html"><a href="aki.html#association-of-aki-with-mortality-morbidity"><i class="fa fa-check"></i><b>2.2</b> Association of AKI with mortality &amp; morbidity</a></li>
<li class="chapter" data-level="2.3" data-path="aki.html"><a href="aki.html#other-trials-in-aki"><i class="fa fa-check"></i><b>2.3</b> Other trials in AKI</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="contrast-associated-nephropathy.html"><a href="contrast-associated-nephropathy.html"><i class="fa fa-check"></i><b>3</b> Contrast-associated nephropathy</a></li>
<li class="chapter" data-level="4" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html"><i class="fa fa-check"></i><b>4</b> Hepatorenal syndrome</a>
<ul>
<li class="chapter" data-level="4.1" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html#has-and-vasopressors"><i class="fa fa-check"></i><b>4.1</b> HAS and vasopressors</a></li>
<li class="chapter" data-level="4.2" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html#volume-status-in-cirrhosis"><i class="fa fa-check"></i><b>4.2</b> Volume status in cirrhosis</a></li>
</ul></li>
<li class="part"><span><b>II CKD</b></span></li>
<li class="chapter" data-level="5" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html"><i class="fa fa-check"></i><b>5</b> CKD, eGFR, proteinuria</a>
<ul>
<li class="chapter" data-level="5.1" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#egfr"><i class="fa fa-check"></i><b>5.1</b> eGFR</a></li>
<li class="chapter" data-level="5.2" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#association-of-egfr-and-proteinuria-with-hard-outcomes"><i class="fa fa-check"></i><b>5.2</b> Association of eGFR and proteinuria with hard outcomes</a></li>
<li class="chapter" data-level="5.3" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#estimating-risk-of-ckd-progression"><i class="fa fa-check"></i><b>5.3</b> Estimating risk of CKD progression</a></li>
<li class="chapter" data-level="5.4" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#competing-risk-of-death"><i class="fa fa-check"></i><b>5.4</b> Competing risk of death</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html"><i class="fa fa-check"></i><b>6</b> Slowing CKD progression</a>
<ul>
<li class="chapter" data-level="6.1" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#lifestyle-measures"><i class="fa fa-check"></i><b>6.1</b> Lifestyle measures</a></li>
<li class="chapter" data-level="6.2" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#ABP_CKD"><i class="fa fa-check"></i><b>6.2</b> Does blood pressure reduction delay <strong>progression of kidney disease</strong>?</a></li>
<li class="chapter" data-level="6.3" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#rasi-progression-in-non-diabetic-disease"><i class="fa fa-check"></i><b>6.3</b> RASi &amp; progression in non-diabetic disease</a>
<ul>
<li class="chapter" data-level="6.3.1" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#starting-rasi"><i class="fa fa-check"></i><b>6.3.1</b> Starting RASi</a></li>
<li class="chapter" data-level="6.3.2" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#stopping-rasi"><i class="fa fa-check"></i><b>6.3.2</b> Stopping RASi</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#SGLT_CKD"><i class="fa fa-check"></i><b>6.4</b> SGLT2i</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html"><i class="fa fa-check"></i><b>7</b> Diabetic kidney disease</a>
<ul>
<li class="chapter" data-level="7.1" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#glycaemic-control"><i class="fa fa-check"></i><b>7.1</b> Glycaemic control</a></li>
<li class="chapter" data-level="7.2" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#DKD_RASi"><i class="fa fa-check"></i><b>7.2</b> RAS blockade</a></li>
<li class="chapter" data-level="7.3" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#drasi_DKD"><i class="fa fa-check"></i><b>7.3</b> Dual RAAS blockade</a></li>
<li class="chapter" data-level="7.4" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#SGLT_DKD"><i class="fa fa-check"></i><b>7.4</b> SGLTi</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="renal-anaemia.html"><a href="renal-anaemia.html"><i class="fa fa-check"></i><b>8</b> Renal anaemia</a>
<ul>
<li class="chapter" data-level="8.1" data-path="renal-anaemia.html"><a href="renal-anaemia.html#erythropoetin"><i class="fa fa-check"></i><b>8.1</b> Erythropoetin</a></li>
<li class="chapter" data-level="8.2" data-path="renal-anaemia.html"><a href="renal-anaemia.html#iron"><i class="fa fa-check"></i><b>8.2</b> Iron</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="ckd-mbd.html"><a href="ckd-mbd.html"><i class="fa fa-check"></i><b>9</b> CKD-MBD</a>
<ul>
<li class="chapter" data-level="9.1" data-path="ckd-mbd.html"><a href="ckd-mbd.html#cinacalcet"><i class="fa fa-check"></i><b>9.1</b> Cinacalcet</a></li>
<li class="chapter" data-level="9.2" data-path="ckd-mbd.html"><a href="ckd-mbd.html#phosphate-binders"><i class="fa fa-check"></i><b>9.2</b> Phosphate binders</a></li>
</ul></li>
<li class="part"><span><b>III Blood pressure &amp; CVS risk</b></span></li>
<li class="chapter" data-level="10" data-path="HTN.html"><a href="HTN.html"><i class="fa fa-check"></i><b>10</b> Hypertension in the general population</a>
<ul>
<li class="chapter" data-level="10.1" data-path="HTN.html"><a href="HTN.html#rationale-for-treating-htn"><i class="fa fa-check"></i><b>10.1</b> Rationale for treating HTN</a></li>
<li class="chapter" data-level="10.2" data-path="HTN.html"><a href="HTN.html#treatment-thresholds-in-general-population"><i class="fa fa-check"></i><b>10.2</b> Treatment thresholds (in general population)</a></li>
<li class="chapter" data-level="10.3" data-path="HTN.html"><a href="HTN.html#mode-of-intervention"><i class="fa fa-check"></i><b>10.3</b> Mode of intervention</a></li>
<li class="chapter" data-level="10.4" data-path="HTN.html"><a href="HTN.html#special-populations"><i class="fa fa-check"></i><b>10.4</b> Special populations</a></li>
<li class="chapter" data-level="10.5" data-path="HTN.html"><a href="HTN.html#renal-dennervation"><i class="fa fa-check"></i><b>10.5</b> Renal dennervation</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html"><i class="fa fa-check"></i><b>11</b> CVS risk in the general population</a>
<ul>
<li class="chapter" data-level="11.1" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html#assessing-risk"><i class="fa fa-check"></i><b>11.1</b> Assessing risk</a></li>
<li class="chapter" data-level="11.2" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html#interventions-to-reduce-risk"><i class="fa fa-check"></i><b>11.2</b> Interventions to reduce risk</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html"><i class="fa fa-check"></i><b>12</b> CVS risk in CKD</a>
<ul>
<li class="chapter" data-level="12.1" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#statins"><i class="fa fa-check"></i><b>12.1</b> Statins</a></li>
<li class="chapter" data-level="12.2" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#coronary-intervention"><i class="fa fa-check"></i><b>12.2</b> Coronary intervention</a></li>
<li class="chapter" data-level="12.3" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#afib"><i class="fa fa-check"></i><b>12.3</b> AFib</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="renovascular-disease.html"><a href="renovascular-disease.html"><i class="fa fa-check"></i><b>13</b> Renovascular disease</a></li>
<li class="part"><span><b>IV BODY FLUIDS</b></span></li>
<li class="chapter" data-level="14" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html"><i class="fa fa-check"></i><b>14</b> Fluids, electrolytes &amp; acid-base</a>
<ul>
<li class="chapter" data-level="14.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyponatraemia"><i class="fa fa-check"></i><b>14.1</b> Hyponatraemia</a></li>
<li class="chapter" data-level="14.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyperkalaemia"><i class="fa fa-check"></i><b>14.2</b> Hyperkalaemia</a></li>
<li class="chapter" data-level="14.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#fluids"><i class="fa fa-check"></i><b>14.3</b> IV fluid therapy</a></li>
<li class="chapter" data-level="14.4" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#diuretic-therapy"><i class="fa fa-check"></i><b>14.4</b> Diuretic therapy</a></li>
<li class="chapter" data-level="14.5" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#metabolic-acidosis"><i class="fa fa-check"></i><b>14.5</b> Metabolic acidosis</a>
<ul>
<li class="chapter" data-level="14.5.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#acidosis-of-ckd"><i class="fa fa-check"></i><b>14.5.1</b> Acidosis of CKD</a></li>
<li class="chapter" data-level="14.5.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#renal-tubular-acidosis"><i class="fa fa-check"></i><b>14.5.2</b> Renal tubular acidosis</a></li>
<li class="chapter" data-level="14.5.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#severe-metabolic-acidosis"><i class="fa fa-check"></i><b>14.5.3</b> Severe metabolic acidosis</a></li>
</ul></li>
</ul></li>
<li class="part"><span><b>V SPECIFIC KIDNEY DISEASES</b></span></li>
<li class="chapter" data-level="15" data-path="glomerular-disease.html"><a href="glomerular-disease.html"><i class="fa fa-check"></i><b>15</b> Glomerular disease</a>
<ul>
<li class="chapter" data-level="15.1" data-path="glomerular-disease.html"><a href="glomerular-disease.html#proteinuria"><i class="fa fa-check"></i><b>15.1</b> Proteinuria</a></li>
<li class="chapter" data-level="15.2" data-path="glomerular-disease.html"><a href="glomerular-disease.html#igan"><i class="fa fa-check"></i><b>15.2</b> IgAN</a></li>
<li class="chapter" data-level="15.3" data-path="glomerular-disease.html"><a href="glomerular-disease.html#membranous"><i class="fa fa-check"></i><b>15.3</b> Membranous</a></li>
<li class="chapter" data-level="15.4" data-path="glomerular-disease.html"><a href="glomerular-disease.html#minimal-change"><i class="fa fa-check"></i><b>15.4</b> Minimal change</a></li>
<li class="chapter" data-level="15.5" data-path="glomerular-disease.html"><a href="glomerular-disease.html#fsgs"><i class="fa fa-check"></i><b>15.5</b> FSGS</a></li>
<li class="chapter" data-level="15.6" data-path="glomerular-disease.html"><a href="glomerular-disease.html#Apol1"><i class="fa fa-check"></i><b>15.6</b> APOL1 nephropathy</a></li>
<li class="chapter" data-level="15.7" data-path="glomerular-disease.html"><a href="glomerular-disease.html#ahus"><i class="fa fa-check"></i><b>15.7</b> aHUS</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html"><i class="fa fa-check"></i><b>16</b> ANCA vasculitis</a>
<ul>
<li class="chapter" data-level="16.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#induction"><i class="fa fa-check"></i><b>16.1</b> Induction</a>
<ul>
<li class="chapter" data-level="16.1.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#glucocorticoids-plasma-exchange"><i class="fa fa-check"></i><b>16.1.1</b> Glucocorticoids &amp; Plasma-exchange</a></li>
<li class="chapter" data-level="16.1.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#cyclophosphamide"><i class="fa fa-check"></i><b>16.1.2</b> Cyclophosphamide</a></li>
<li class="chapter" data-level="16.1.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#rituximab"><i class="fa fa-check"></i><b>16.1.3</b> Rituximab</a></li>
<li class="chapter" data-level="16.1.4" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#other-agents"><i class="fa fa-check"></i><b>16.1.4</b> Other agents</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#maintenance"><i class="fa fa-check"></i><b>16.2</b> Maintenance</a></li>
<li class="chapter" data-level="16.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#adjunctive-therapies"><i class="fa fa-check"></i><b>16.3</b> Adjunctive therapies</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html"><i class="fa fa-check"></i><b>17</b> Lupus nephritis</a>
<ul>
<li class="chapter" data-level="17.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#induction-1"><i class="fa fa-check"></i><b>17.1</b> Induction</a></li>
<li class="chapter" data-level="17.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#maintenance-adjunctive-rx"><i class="fa fa-check"></i><b>17.2</b> Maintenance &amp; adjunctive Rx</a></li>
<li class="chapter" data-level="17.3" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#newer-therapies"><i class="fa fa-check"></i><b>17.3</b> Newer therapies</a>
<ul>
<li class="chapter" data-level="17.3.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#b-cell-therapies"><i class="fa fa-check"></i><b>17.3.1</b> B-cell therapies</a></li>
<li class="chapter" data-level="17.3.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#cnis"><i class="fa fa-check"></i><b>17.3.2</b> CNIs</a></li>
</ul></li>
<li class="chapter" data-level="17.4" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#glucocorticoid-toxicity"><i class="fa fa-check"></i><b>17.4</b> Glucocorticoid toxicity</a></li>
<li class="chapter" data-level="17.5" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#contraception"><i class="fa fa-check"></i><b>17.5</b> Contraception</a></li>
</ul></li>
<li class="chapter" data-level="18" data-path="adpkd.html"><a href="adpkd.html"><i class="fa fa-check"></i><b>18</b> ADPKD</a>
<ul>
<li class="chapter" data-level="18.1" data-path="adpkd.html"><a href="adpkd.html#blood-pressure-targets-and-rasi"><i class="fa fa-check"></i><b>18.1</b> Blood pressure targets and RASi</a></li>
<li class="chapter" data-level="18.2" data-path="adpkd.html"><a href="adpkd.html#vasopressin-antagonist-therapy"><i class="fa fa-check"></i><b>18.2</b> Vasopressin antagonist therapy</a></li>
</ul></li>
<li class="chapter" data-level="19" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html"><i class="fa fa-check"></i><b>19</b> Miscellaneous conditions</a>
<ul>
<li class="chapter" data-level="19.1" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#myeloma"><i class="fa fa-check"></i><b>19.1</b> Myeloma</a></li>
<li class="chapter" data-level="19.2" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#pregnancy"><i class="fa fa-check"></i><b>19.2</b> Pregnancy</a></li>
<li class="chapter" data-level="19.3" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#ain"><i class="fa fa-check"></i><b>19.3</b> AIN</a></li>
<li class="chapter" data-level="19.4" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#tuberous-sclerosis"><i class="fa fa-check"></i><b>19.4</b> Tuberous sclerosis</a></li>
<li class="chapter" data-level="19.5" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#other"><i class="fa fa-check"></i><b>19.5</b> Other</a></li>
</ul></li>
<li class="part"><span><b>VI DIALYSIS</b></span></li>
<li class="chapter" data-level="20" data-path="acute_RRT.html"><a href="acute_RRT.html"><i class="fa fa-check"></i><b>20</b> Acute dialysis</a>
<ul>
<li class="chapter" data-level="20.1" data-path="acute_RRT.html"><a href="acute_RRT.html#dose"><i class="fa fa-check"></i><b>20.1</b> Dose</a></li>
<li class="chapter" data-level="20.2" data-path="acute_RRT.html"><a href="acute_RRT.html#timing"><i class="fa fa-check"></i><b>20.2</b> Timing</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html"><i class="fa fa-check"></i><b>21</b> Chronic dialysis</a>
<ul>
<li class="chapter" data-level="21.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#chronic-haemodialysis"><i class="fa fa-check"></i><b>21.1</b> Chronic Haemodialysis</a>
<ul>
<li class="chapter" data-level="21.1.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#modality"><i class="fa fa-check"></i><b>21.1.1</b> Modality</a></li>
<li class="chapter" data-level="21.1.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#dose-1"><i class="fa fa-check"></i><b>21.1.2</b> Dose</a></li>
<li class="chapter" data-level="21.1.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#initiation"><i class="fa fa-check"></i><b>21.1.3</b> Initiation</a></li>
</ul></li>
<li class="chapter" data-level="21.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#peritoneal-dialysis"><i class="fa fa-check"></i><b>21.2</b> Peritoneal Dialysis</a></li>
<li class="chapter" data-level="21.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#conservative-care"><i class="fa fa-check"></i><b>21.3</b> Conservative care</a></li>
</ul></li>
<li class="part"><span><b>VII TRANSPLANT</b></span></li>
<li class="chapter" data-level="22" data-path="transplant---donors.html"><a href="transplant---donors.html"><i class="fa fa-check"></i><b>22</b> Transplant - donors</a>
<ul>
<li class="chapter" data-level="22.1" data-path="transplant---donors.html"><a href="transplant---donors.html#donor-types"><i class="fa fa-check"></i><b>22.1</b> Donor types</a></li>
<li class="chapter" data-level="22.2" data-path="transplant---donors.html"><a href="transplant---donors.html#donor-aki"><i class="fa fa-check"></i><b>22.2</b> Donor AKI</a></li>
<li class="chapter" data-level="22.3" data-path="transplant---donors.html"><a href="transplant---donors.html#ischaemic-time"><i class="fa fa-check"></i><b>22.3</b> Ischaemic time</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html"><i class="fa fa-check"></i><b>23</b> Transplant - immunosuppression &amp; rejection</a>
<ul>
<li class="chapter" data-level="23.1" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#immunosuppression"><i class="fa fa-check"></i><b>23.1</b> Immunosuppression</a></li>
<li class="chapter" data-level="23.2" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#desensitisation"><i class="fa fa-check"></i><b>23.2</b> Desensitisation</a></li>
<li class="chapter" data-level="23.3" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#rejection"><i class="fa fa-check"></i><b>23.3</b> Rejection</a></li>
</ul></li>
<li class="chapter" data-level="24" data-path="transplant---complications.html"><a href="transplant---complications.html"><i class="fa fa-check"></i><b>24</b> Transplant - complications</a>
<ul>
<li class="chapter" data-level="24.1" data-path="transplant---complications.html"><a href="transplant---complications.html#cmv-disease"><i class="fa fa-check"></i><b>24.1</b> CMV disease</a></li>
<li class="chapter" data-level="24.2" data-path="transplant---complications.html"><a href="transplant---complications.html#statin_Tx"><i class="fa fa-check"></i><b>24.2</b> CVS risk</a></li>
</ul></li>
<li class="part"><span><b>VIII OTHER</b></span></li>
<li class="chapter" data-level="25" data-path="historic-trials.html"><a href="historic-trials.html"><i class="fa fa-check"></i><b>25</b> Historic trials</a></li>
<li class="chapter" data-level="26" data-path="seminal-basic-science.html"><a href="seminal-basic-science.html"><i class="fa fa-check"></i><b>26</b> Seminal basic science</a></li>
<li class="chapter" data-level="27" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html"><i class="fa fa-check"></i><b>27</b> Other (non-renal) specialties</a>
<ul>
<li class="chapter" data-level="27.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#critical-care"><i class="fa fa-check"></i><b>27.1</b> Critical care</a>
<ul>
<li class="chapter" data-level="27.1.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#sepsis"><i class="fa fa-check"></i><b>27.1.1</b> Sepsis</a></li>
</ul></li>
<li class="chapter" data-level="27.2" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#cardio"><i class="fa fa-check"></i><b>27.2</b> Cardiology</a></li>
<li class="chapter" data-level="27.3" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#haematology"><i class="fa fa-check"></i><b>27.3</b> Haematology</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">LATINART</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="lupus-nephritis" class="section level1 hasAnchor" number="17">
<h1><span class="header-section-number">Chapter 17</span> Lupus nephritis<a href="lupus-nephritis.html#lupus-nephritis" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<div id="induction-1" class="section level2 hasAnchor" number="17.1">
<h2><span class="header-section-number">17.1</span> Induction<a href="lupus-nephritis.html#induction-1" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Induction regimes using <strong>cyclophosphamide</strong> are more effective than steroids alone:</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/3511372"><strong>Austin et al.</strong></a> (1986): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - IV CYC plus steroids <em>vs.</em> steroids alone in lupus nephritis. Cyclophosphamide delayed progression to ESRF.</p>
</div>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/8815753"><strong>NIH study</strong></a> (1996): <img src="Logo_RCT.png" style="height:1.2em" /> - pulsed IV CYC <em>vs.</em> pulsed IV steroids <em>vs.</em> both in proliferative lupus nephritis. Steroids alone were less effective at inducing remission.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/12209517"><strong>Euro-Lupus</strong></a> (2002) and <a href="https://www.ncbi.nlm.nih.gov/pubmed/19155235">10-yr follow-up</a> (2010): <img src="Logo_RCT.png" style="height:1.2em" /> - high-dose <em>vs.</em> low-dose cyclophosphamide induction (with azathioprine maintenance) in proliferative lupus nephritis. Low-dose regime was non-inferior.</p>
<p><strong>MMF for induction</strong> is non-inferior to cyclophosphamide:</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16306519"><strong>Ginzler et al.</strong></a> (2005): <img src="Logo_RCT.png" style="height:1.2em" /> - MMF <em>vs.</em> IV cyclophosphamide in lupus nephritis (class III–V). MMF was more effetive than cyclophosphamide at inducing remission.</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/19369404"><strong>ALMS</strong></a> (2009): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - MMF <em>vs.</em> IV cyclophosphamide in lupus nephritis (class III–V). MMF was non-inferior.</p>
</div>
<p><em>Post-hoc</em> <a href="https://www.ncbi.nlm.nih.gov/pubmed/23375819">subgroup analysis or ALMS</a> suggest MMF may be superior when GFR &lt;30. On the other hand <a href="https://www.ncbi.nlm.nih.gov/pubmed/22879439">meta-analyses</a> suggests greater relapse rate after MMF.</p>
<p>Contemporary protocols favour relatively less <strong>steroid</strong>:</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/21976398"><strong>MYLUPUS</strong></a> (2011): <img src="Logo_RCT.png" style="height:1.2em" /> - standard-dose (starting ~1 mg/kg/day) <em>vs.</em> low-dose (starting ~0.5 mg/kg/day) pred in proliferative LN. Both groups treated with enteric-coated mycophenolate (~720 mg bd then tid). Small study (n = 40 + 40) but similar efficacy at inducing remission by 6 months.</p>
</div>
<div id="maintenance-adjunctive-rx" class="section level2 hasAnchor" number="17.2">
<h2><span class="header-section-number">17.2</span> Maintenance &amp; adjunctive Rx<a href="lupus-nephritis.html#maintenance-adjunctive-rx" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>MMF is superior to aza in maintenance:
<a href="https://www.ncbi.nlm.nih.gov/pubmed/22087680"><strong>Dooley et al.</strong></a> (2011): <img src="Logo_RCT.png" style="height:1.2em" /> - MMF (2g/day) <em>vs</em> aza (2 mg/kg/day) for maintenance of remission in lupus nephritis. MMF superior at maintaining remission (treatment failure during 3 year follow-up ~16 <em>vs</em> 32%) and associated with fewer serious adverse events.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/1984192"><strong>Canadian HCQ trial</strong></a> (1991): <img src="Logo_RCT.png" style="height:1.2em" /> - withdrawal <em>vs</em> continuation of HCQ in stable lupus. Withdrawal lead to ~2.5x risk of lupus flare.</p>
</div>
<div id="newer-therapies" class="section level2 hasAnchor" number="17.3">
<h2><span class="header-section-number">17.3</span> Newer therapies<a href="lupus-nephritis.html#newer-therapies" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<div id="b-cell-therapies" class="section level3 hasAnchor" number="17.3.1">
<h3><span class="header-section-number">17.3.1</span> B-cell therapies<a href="lupus-nephritis.html#b-cell-therapies" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><strong>Rituximab</strong> may be an alternative option in steroid-sparing regimes and for rescue therapy.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/22231479"><strong>LUNAR</strong></a> (2012): <img src="Logo_RCT.png" style="height:1.2em" /> - rituximab <em>vs.</em> placebo in proliferative lupus nephritis (alongside MMF and steroids). No difference in primary end-point (of renal response at 1 year).</p>
<p><strong>RITUXILUP</strong> - not yet reported.</p>
<p><strong>Belimumab</strong> targets B-cell activating factor (BAFF, aka B-lymphocyte stimulator, BLyS).</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/32937045"><strong>BLISS-LN</strong></a> (2020): <img src="Logo_RCT.png" style="height:1.2em" /> - belimumab <em>vs</em> placebo (plus standard induction with CYC / MMF) in lupus nephritis. Primary outcome was changed after study registration. Final primary outcome was uPCR &lt; 100 with stable eGFR and no rescue Rx at 2 yrs. Belimumab was efficacious (40 vs. 30% primary end-point) with good safety profile. The results would not have been statistically significant for the original primary end-point (complete / partial / non-response).</p>
</div>
<div id="cnis" class="section level3 hasAnchor" number="17.3.2">
<h3><span class="header-section-number">17.3.2</span> CNIs<a href="lupus-nephritis.html#cnis" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/25383558/"><strong>Multi-target therapy</strong></a> (2015): <img src="Logo_RCT.png" style="height:1.2em" /> - tacro + MMF + steroid <em>vs</em> IV CYC + steroid in Chinese population (n = 368). Tacro and MMF induced greater complete remission (25 <em>vs</em> 45 %) at 24 weeks.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/33971155"><strong>AURORA</strong></a> (2021): <img src="Logo_RCT.png" style="height:1.2em" /> - voclosporin <em>vs</em> placebo in lupus nephritis, in addition to MMF and pred. Primary endpoint was complete renal remission at 1 yr. Voclosporin was effective (primary endpoint in ~40 vs. 20%) with no safety signal. Primary endpoint dominated by proteinuria response which may of course be haemodynamic.</p>
</div>
</div>
<div id="glucocorticoid-toxicity" class="section level2 hasAnchor" number="17.4">
<h2><span class="header-section-number">17.4</span> Glucocorticoid toxicity<a href="lupus-nephritis.html#glucocorticoid-toxicity" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><a href="https://doi.org/10.1016/S2665-9913(19)30105-5"><strong>Apostolopoulos et al.</strong></a> (2020): <img src="Logo_OBS.png" style="height:1.2em" /> - cohort study in South-East Asia / Australasia (n = 1700): in patients with SLE (of whom 50% had baseline kidney disease - not necessarily lupus nephritis), glucocorticoid use was associated with damage accrual, independent of disease activity.</p>
</div>
<div id="contraception" class="section level2 hasAnchor" number="17.5">
<h2><span class="header-section-number">17.5</span> Contraception<a href="lupus-nephritis.html#contraception" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16354891"><strong>Petrie et al.</strong></a> &amp; <a href="https://www.ncbi.nlm.nih.gov/pubmed/1654890"><strong>Sanchez-Guerro et al.</strong></a> (2005): <img src="Logo_RCT.png" style="height:1.2em" /> - two RCTs testing contraceptive methods in women with SLE. Only patients with inactive or stable disease recruited; excluded if APS or prior VTE. Use of estrogen-containing contraceptives did not provoke disease flare.</p>

</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="anca-vasculitis.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="adpkd.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": null,
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 1
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
